Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.31 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.31 |
| ▸ | TTR | P02766 | 1/20 | 0.31 |
| ▸ | ALB | P02768 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 3/20 | 0.31 |
| ▸ | DRD3 | P35462 | 3/20 | 0.31 |
| ▸ | ADRB2 | P07550 | 4/20 | 0.31 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.31 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18927432 | 0.90 | KCNH2 (0.32) | TSHRHSD17B10CNR1CNR2CYP2A6 | |
| SCHEMBL22432045 | 0.83 | CNR1 (0.46) | CNR1CNR2DRD2DRD3S1PR1 | |
| SCHEMBL18500965 | 0.81 | TSHR (0.45) | TSHRHSD17B10CYP19A1CYP2A6GRM2 | |
| SCHEMBL19272949 | 0.80 | ALDH1A1 (0.36) | TSHRHSD17B10CYP2A6TTRALB | |
| SCHEMBL10472613 | 0.80 | MGLL (0.36) | TSHRHSD17B10 | |
| SCHEMBL21741180 | 0.77 | HRH4 (0.31) | TSHRADRB2 | |
| SCHEMBL19304426 | 0.77 | PGR (0.33) | CNR1CNR2 | |
| SCHEMBL25086538 | 0.77 | CNR1 (0.45) | TSHRHSD17B10CNR1CNR2DRD2 | |
| SCHEMBL19464663 | 0.75 | TSHR (0.50) | TSHRHSD17B10CYP19A1CYP2A6GRM2 | |
| SCHEMBL8738821 | 0.75 | TTR (0.34) | CYP2A6TTRALB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170349552-A1 | Treatment of Amyotrophic Lateral Sclerosis | NORTHWESTERN UNIVERSITY (US) | 2017-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170349552-A1 | Treatment of Amyotrophic Lateral Sclerosis | SMN1; SMN2, SOD1, NLN | TSHR 4791/4885HSD17B10 1474/4885CNR1 2707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.